Related Experiment Video
Updated: May 29, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
Colchicine in the management of mucous membrane pemphigoid
Georgios Chaidemenos1, Theodoros Sidiropoulos, Paraskevoula Katsioula
1State Hospital for Skin and Venereal Diseases, Thessaloniki, Greece.
Abstract:
Mucous membrane pemphigoid (MMP) usually runs a chronic and potentially devastating course. Its management requires long-term oral corticosteroids. Safe and effective adjuvant or steroid-sparing agents are needed. In this retrospective observational study with a follow-up extending to 16 years (mean: 4 years), 60% (9/15) of all patients with MMP were lesion-free under oral steroid therapy combined with a second immunosuppressant agent. Colchicine was the most effective, clearing from at least one individual mucosal site lesions in 67% (8/12) of patients. Colchicine may be suggested as a first-line corticosteroid-sparing regimen in the management of MMP.
Related Concept Videos
Drugs that Destabilize Microtubules
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
